Amarin Plummets After Patent Appeal Shows Key Drug Sales at Risk
(Bloomberg) -- Amarin Corp. fell the most since March after it faced tough questioning from a U.S. appeals court reviewing the validity of patents on its only product, the heart treatment Vascepa.
The three-judge panel of the U.S. Court of Appeals for the Federal Circuit had no questions at argument Wednesday for the defendants, generic-drug makers Hikma Pharmaceuticals Plc and Dr. Reddy's Laboratories Ltd.
“I can't remember an oral argument where the judges had no questions for one party,” said Michael Cohen of MDC Financial, a legal expert who listened to the hearing. “We believe if they were going to overturn the ruling in the party's favor they would more likely be in their face asking questions.”
Amarin stock fell as much as 31%, the worst decline since the March court ruling that invalidated its six patents on the heart treatment Vascepa, which weren't set to expire until 2030. The ruling opened the door to low-cost generic versions of the drug, and wiped out $3.5 billion in market value.
“We do not gain any more confidence that Amarin will prevail, actually we are slightly less confident,” Stifel analyst Derek Archila wrote in a research note. “We would not be buying shares here.”
The trial court accepted the defendants' argument that the patents were obvious because a version of Vascepa's active ingredient, a type of fish oil, has been known since the 1990s.
“I don't think this will be controversial among the panel, I think it's going to be a clear affirmance,” Dan Ravicher, a law professor at the University of Miami, said by phone. “It's weird for such an important case that could be worth billions of dollars to be so straight forward.”
The case is Amarin Pharma, Inc. v. Hikma Pharm. USA Inc., Fed. Cir., No. 20-1723, argued 9/2/20.
©2020 Bloomberg L.P.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.